Abbott Laboratories
ABT- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000001800
In the last 90 days, Abbott Laboratories insiders filed 0 open-market purchases and 3 sales; 2,985 institutions reported holding it in 13F filings for Q2 2026, worth $125.2B in total; 3 superinvestors hold it, including Southeastern Asset Management (Longleaf) and Soros Fund Management.
Holders of 5% or more of ABT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Abbott Laboratories, largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Abbott Laboratories on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
Schedule 13D and 13G filings on Abbott Laboratories, newest first.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Dec 3, 202511:02 AM ET | Vanguard Group Inc | 13G/A | 10.05%174.9M shares | – | Nov 28, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Abbott Laboratories shares.
No Form 144 notices for Abbott Laboratories are on file.